Comprehensive resource on JAK family kinases, the JAK-STAT signaling pathway, JAK inhibitor therapeutics, and their roles in immunology, oncology, and hematology.
JAK family members
STAT transcription factors
Approved JAK inhibitors
The JAK-STAT pathway transduces extracellular cytokine signals to transcriptional responses in the nucleus
Type I/II cytokine receptors bind ligands (interferons, interleukins, growth factors), inducing receptor dimerization and JAK transphosphorylation.
Activated JAKs phosphorylate tyrosine residues on receptor intracellular domains, creating docking sites for STAT proteins via their SH2 domains.
Phosphorylated STATs dimerize and translocate to the nucleus, binding specific DNA elements (GAS, ISRE) to activate target gene transcription.
Suppressor of cytokine signaling (SOCS) proteins provide negative feedback, targeting JAKs for ubiquitin-mediated proteasomal degradation.
JAK-STAT signaling is essential for T cell differentiation, B cell development, NK cell activity, and dendritic cell maturation.
Dysregulated JAK-STAT signaling drives autoimmune diseases, myeloproliferative neoplasms, and certain cancers through constitutive activation.
JAK family members
Cytokines using JAK-STAT
Approved JAK inhibitors
Global JAKi market (2025)
FDA-approved and investigational JAK inhibitors across multiple therapeutic indications
| Drug | Brand | Selectivity | Indications | Status |
|---|---|---|---|---|
| Tofacitinib | Xeljanz | JAK1/3 > JAK2 | RA, PsA, UC | Approved |
| Baricitinib | Olumiant | JAK1/2 | RA, Alopecia, COVID-19 | Approved |
| Ruxolitinib | Jakafi | JAK1/2 | Myelofibrosis, PV, GvHD | Approved |
| Upadacitinib | Rinvoq | JAK1 selective | RA, AD, UC, Crohn's | Approved |
| Abrocitinib | Cibinqo | JAK1 selective | Atopic Dermatitis | Approved |
| Deucravacitinib | Sotyktu | TYK2 selective | Plaque Psoriasis | Approved |
Complete walkthrough of the JAK-STAT cascade from cytokine binding through STAT-mediated transcription, including negative regulation.
Read ArticleReview of approved and emerging JAK inhibitors for rheumatoid arthritis, atopic dermatitis, IBD, and other autoimmune conditions.
Read ArticleOverview of next-generation selective JAK3 inhibitors entering Phase II/III trials for T-cell mediated diseases.
Read ArticlePropose collaboration, submit research findings, or request access to JAK-STAT resources.
Book a discussion on JAK-STAT pathway research, inhibitor development, or clinical collaboration.